UQCC5: A Drug Target and Potential Biomarker (G440957)

Target Name: UQCC5

NCBI ID: G440957

UQCC5

UQCC5: A Drug Target and Potential Biomarker

Ubiquinol-cytochrome c (Q) reductase complex assembly factor 5 (UQCC5) is a protein that plays a crucial role in the regulation of mitochondrial function and energy metabolism. UQCC5 is a key component of the UQCC complex, which is responsible for assembling the Q-carrying electrons from the cytochrome c system to the mitochondrial inner mitochondrial membrane. In recent years, research has identified UQCC5 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

The UQCC complex is a complex of proteins that work together to facilitate the transfer of electrons from the cytochrome c system to the mitochondrial inner membrane. The Q-carrying electrons are crucial for the production of ATP energy and the maintenance of the cell's energy balance. UQCC5 is a key component of the UQCC complex, as it helps to regulate the assembly and disassembly of the complex.

Recent studies have identified UQCC5 as a potential drug target for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. For example, studies have shown that inhibiting UQCC5 activity can lead to a reduction in the growth and metastasis of cancer cells. Additionally, research has identified UQCC5 as a potential biomarker for neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

Another study has shown that UQCC5 is involved in the regulation of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain. The study found that UQCC5 helps to regulate the formation and function of the blood-brain barrier, which could have implications for the treatment of various neurological disorders.

In addition to its potential drug-targeting and biomarker properties, UQCC5 is also of interest as a potential therapeutic agent for diseases that affect the mitochondria. Mitochondria are involved in the production of ATP energy and are also responsible for the production of the molecules that damage and contribute to the aging process. Therefore, diseases that affect the mitochondria, such as Alzheimer's disease and Parkinson's disease, are of particular interest to researchers as potential therapeutic targets.

In conclusion, UQCC5 is a protein that plays a crucial role in the regulation of mitochondrial function and energy metabolism. Recent studies have identified UQCC5 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Further research is needed to fully understand the role of UQCC5 in disease progression and to develop effective therapies that target this protein.

Protein Name: Ubiquinol-cytochrome C Reductase Complex Assembly Factor 5

Functions: Required for the assembly and stability of the mitochondrial ubiquinol-cytochrome c reductase complex (complex III (CIII) or cytochrome b-c1 complex), a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain (ETC) which drives oxidative phosphorylation (By similarity). Mediates early complex III biogenesis (By similarity). Participates in regulating the levels of electron transport chain proteins, and therefore energy supply, in response to changes in energy demand (By similarity). Also involved in the first steps of cytochrome c oxidase complex (complex IV) assembly (PubMed:34969438)

The "UQCC5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UQCC5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets